A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
NCT ID: NCT03159403
Last Updated: 2018-03-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
325 participants
OBSERVATIONAL
2017-04-12
2018-03-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects
NCT02470702
Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis)
NCT03568942
GSK2251052 in Complicated Urinary Tract Infection
NCT01381549
A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants
NCT01762839
Oritavancin for Staphylococcus Aureus Infections in Opioid Users
NCT03761953
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oritavancin
Participants who received at least one dose (at least one for 3 hours per dose) of oritavancin intravenous (IV) as monotherapy or part of a broader regimen. The maximum number of doses to be received by a participant is not known at this time.
Oritavancin
This study is an observational study. All participants were administered oritavancin prior to enrollment in this study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oritavancin
This study is an observational study. All participants were administered oritavancin prior to enrollment in this study.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 60 days has elapsed since the participant received the last dose of oritavancin therapy (prior to data entry into the electronic Case Report Form).
Exclusion Criteria
* The participant received oritavancin as a part of a Medicines Company-sponsored single or multi-centered pharmacoeconomic outcomes study.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Melinta Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Information
Role: STUDY_DIRECTOR
Global Health Science Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham Infectious Disease and Infusion
Birmingham, Alabama, United States
Santa Barbara Cottage Hospital
Santa Barbara, California, United States
Florida Infectious Disease Care
Fort Myers, Florida, United States
Infectious Diseases Associates of North Central Florida, LLC
Ocala, Florida, United States
WellStar Health System - Kennestone
Marietta, Georgia, United States
Snake River Research, PLLC
Idaho Falls, Idaho, United States
St. Vincent Hospital and Health Care Center, Inc.
Indianapolis, Indiana, United States
Methodist Jennie Edmundson Hospital
Council Bluffs, Iowa, United States
IDC Clinical Research, LLC
Wichita, Kansas, United States
Clinical Infectious Disease Specialists
Las Vegas, Nevada, United States
New York-Presbyterian Brooklyn Methodist Hospital
Brooklyn, New York, United States
Erie County Medical Center
Buffalo, New York, United States
Trinity Health Medical Group
Minot, North Dakota, United States
Infectious Diseases Consultants of OKC
Oklahoma City, Oklahoma, United States
TruCare Internal Medicine and Infectious Diseases
DuBois, Pennsylvania, United States
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Center for Infectious Diseases & Travel Medicine
El Paso, Texas, United States
Houston Center For Infectious Diseases
The Woodlands, Texas, United States
Infectious Disease and Pulmonary
Victoria, Texas, United States
Foot & Ankle Institute
St. George, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MDCO-ORI-15-05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.